Form 8-K - Current report:
SEC Accession No. 0001437749-25-038478
Filing Date
2025-12-22
Accepted
2025-12-22 08:55:52
Documents
18
Period of Report
2025-12-21
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K mbrx20251221_8k.htm   iXBRL 8-K 34270
2 EXHIBIT 4.1 ex_901475.htm EX-4.1 141808
3 EXHIBIT 4.2 ex_901476.htm EX-4.2 150635
4 EXHIBIT 4.3 ex_901551.htm EX-4.3 143787
5 EXHIBIT 10.1 ex_901477.htm EX-10.1 31541
10 logosm01.jpg GRAPHIC 6359
  Complete submission text file 0001437749-25-038478.txt   751823

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA mbrx-20251221.xsd EX-101.SCH 3580
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE mbrx-20251221_def.xml EX-101.DEF 11425
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE mbrx-20251221_lab.xml EX-101.LAB 15311
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mbrx-20251221_pre.xml EX-101.PRE 11585
20 EXTRACTED XBRL INSTANCE DOCUMENT mbrx20251221_8k_htm.xml XML 2846
Mailing Address 5300 MEMORIAL DRIVE SUITE 950 HOUSTON TX 77007
Business Address 5300 MEMORIAL DRIVE SUITE 950 HOUSTON TX 77007 713-300-5160
Moleculin Biotech, Inc. (Filer) CIK: 0001659617 (see all company filings)

EIN.: 474671997 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37758 | Film No.: 251589623
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)